We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+4.35%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$7.24B
AUM Growth
+$171M
Cap. Flow
+$215M
Cap. Flow %
2.98%
Top 10 Hldgs %
34.84%
Holding
226
New
18
Increased
74
Reduced
41
Closed
9

Top Buys

Rank Stock Value
1
RLAY icon
Relay Therapeutics
RLAY
+$49.6M
2
EXAS
Exact Sciences
EXAS
+$26.3M
3
IONS icon
Ionis Pharmaceuticals
IONS
+$25.9M
4
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$24.6M
5
MTEM
Molecular Templates, Inc.
MTEM
+$18.3M

Top Sells

Rank Stock Value
1
HALO icon
Halozyme
HALO
+$35.1M
2
PACB icon
Pacific Biosciences
PACB
+$25.7M
3
EVH icon
Evolent Health
EVH
+$20.6M
4
AKCA
Akcea Therapeutics Inc
AKCA
+$15.9M
5
MDT icon
Medtronic
MDT
+$14.7M

Sector Composition

Rank Sector Weight
1 Healthcare 95.98%
2 Industrials 0.6%
3 Technology 0.53%
4 Communication Services 0.41%
5 Financials 0.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TDOC icon
76
Teladoc Health
TDOC
$1.69B
$26.6M 0.37%
121,354
-29,945
-20% -$6.34M
CHRS icon
77
Coherus Oncology
CHRS
$214M
$25.7M 0.36%
1,403,400
+246,000
+21% +$4.58M
GKOS icon
78
Glaukos
GKOS
$9.13B
$25.5M 0.35%
515,754
+21,943
+4% +$964K
CHNG
79
DELISTED
Change Healthcare Inc. Common Stock
CHNG
$24.6M 0.34%
1,697,939
+242,699
+17% +$3.09M
QTRX icon
80
Quanterix
QTRX
$174M
$24.4M 0.34%
723,674
+246,159
+52% +$7.93M
MASI
81
DELISTED
Masimo
MASI
$24.1M 0.33%
102,153
+4,612
+5% +$1.03M
PEN icon
82
Penumbra
PEN
$12.5B
$23.6M 0.33%
121,194
+23,042
+23% +$4.85M
WVE icon
83
Wave Life Sciences
WVE
$1.12B
$22.1M 0.31%
2,602,858
– –
HMSY
84
DELISTED
HMS Holdings Corp.
HMSY
$22M 0.3%
916,984
+102,720
+13% +$3.02M
KZR
85
DELISTED
Kezar Life Sciences
KZR
$21.9M 0.3%
453,315
+29,121
+7% +$1.39M
IRTC icon
86
iRhythm Holdings
IRTC
$3.62B
$21.6M 0.3%
90,518
-2,622
-3% -$464K
OMCL icon
87
Omnicell
OMCL
$2.08B
$20.8M 0.29%
278,421
+76,290
+38% +$5.29M
GMED icon
88
Globus Medical
GMED
$10.4B
$20.3M 0.28%
409,735
+62,006
+18% +$3.2M
SILK
89
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
$20.2M 0.28%
300,619
+55,281
+23% +$3.02M
TXG icon
90
10x Genomics
TXG
$5.4B
$19.2M 0.27%
153,989
+30,912
+25% +$3.24M
HCAT icon
91
Health Catalyst
HCAT
$162M
$19.1M 0.26%
521,896
+172,727
+49% +$5.87M
QTTB icon
92
Q32 Bio
QTTB
$342M
$18.6M 0.26%
96,507
– –
GH icon
93
Guardant Health
GH
$19.8B
$18.2M 0.25%
162,383
+35,822
+28% +$3.28M
ILMN icon
94
Illumina
ILMN
$28B
$18.1M 0.25%
60,186
-38,550
-39% -$13.3M
GNMK
95
DELISTED
GenMark Diagnostics, Inc
GNMK
$17.9M 0.25%
1,263,811
-225,473
-15% -$3.45M
NVRO
96
DELISTED
NEVRO CORP.
NVRO
$16.8M 0.23%
120,569
+8,807
+8% +$1.18M
NEO icon
97
NeoGenomics
NEO
$1.85B
$15.7M 0.22%
426,892
-58,578
-12% -$2.18M
AMED
98
DELISTED
Amedisys
AMED
$14.6M 0.2%
61,851
+708
+1% +$161K
PHR icon
99
Phreesia
PHR
$651M
$13.7M 0.19%
426,956
+49,787
+13% +$1.48M
ZLAB icon
100
Zai Lab
ZLAB
$2.25B
$13.4M 0.19%
161,200
-13,900
-8% -$1.12M
2 3
4
5 6

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q3 2020 Portfolio in Review

As of Q3 2020, Bellevue Group held 226 positions worth $7.24B, up 2.4% from $7.07B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Bellevue Group's Q3 2020 filing shows 18 new, 74 increased, 41 reduced and 9 closed positions. Its largest new stake was Relay Therapeutics: 1,300,000 shares worth $55.4M. The largest sale was Halozyme, an estimated $35.1M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 96% a quarter earlier, followed by Industrials and Technology.

  • Bellevue Group's largest Q3 2020 buy was Relay Therapeutics: 1,300,000 shares worth $55.4M.
  • Bellevue Group added most to Ionis Pharmaceuticals in Q3 2020, an estimated $25.9M increase.
  • Bellevue Group's biggest Q3 2020 reduction was Halozyme, cutting an estimated $35.1M.
  • Bellevue Group fully exited BioMarin Pharmaceuticals in Q3 2020, selling an estimated $9.48M.
  • Bellevue Group's ten largest holdings make up 35% of its $7.24B portfolio in Q3 2020.
  • Bellevue Group opened 18 new positions and closed 9 in Q3 2020.
  • Bellevue Group's portfolio value rose 2.4% quarter-over-quarter to $7.24B.

Based on Bellevue Group's 13F filing for Q3 2020, filed 16 Nov 2020.